Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARWR - Arrowhead Pharmaceuticals, Inc.
Market Cap 3.52B P/E - EPS this Y -75.00% Ern Qtrly Grth -
Income -470.79M Forward P/E -13.24 EPS next Y 9.20% 50D Avg Chg -6.00%
Sales 35.47M PEG -1.17 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 7.89 EPS next 5Y 7.33% 52W High Chg -32.00%
Recommedations 2.20 Quick Ratio 7.99 Shares Outstanding 124.20M 52W Low Chg 43.00%
Insider Own 4.47% ROA -32.07% Shares Float 110.69M Beta 0.94
Inst Own 78.90% ROE -99.43% Shares Shorted/Prior 9.04M/9.45M Price 32.97
Gross Margin 100.00% Profit Margin - Avg. Volume 906,422 Target Price 50.29
Oper. Margin -1,335.58% Earnings Date Aug 8 Volume 876,899 Change -2.11%
Healthcare | Biotechnology | United States
About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. News
07/24/24 Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
07/01/24 ARWR: Moving Plozasiran Forward in Phase 3 CVOT…
06/30/24 The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
06/28/24 Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
06/25/24 Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
06/24/24 Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
06/03/24 Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
06/03/24 Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
05/31/24 Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
05/29/24 Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
05/28/24 Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
05/20/24 Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
05/16/24 ARWR: Summer Webinar Series to Highlight Development Pipeline…
05/14/24 Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
05/10/24 Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations
05/10/24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
05/09/24 Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
05/02/24 Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
04/29/24 Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
04/26/24 Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
ARWR Chatroom

User Image skeezbag Posted - 10 hours ago

$ARWR see all the sheep sub the 200d Monday. My 1604 friend told me again we can all go fuck ourselves

User Image fredster45 Posted - 11 hours ago

$ARWR did selling before earnings start today?

User Image skeezbag Posted - 12 hours ago

$ARWR the discord sheep can't see the writing on the wall 28.60 from your 1604 friend

User Image TheChosenWon Posted - 16 hours ago

$ARWR the ole 10:10AM tank and recover lives on

User Image skeezbag Posted - 16 hours ago

$ARWR clown stock continues

User Image LeftyT Posted - 18 hours ago

$ALT $ARWR $ANVS $ESPR and many other biotech stocks have been held down by unscrupulous shorting schemes. Citron and Mr. Left have been the tip of the spear for many of those schemes. Today they were fined $20 million for publishing false information to make their short sales more profitable. A drop in the bucket for them, but a sign of life from the SEC for a change. Hopefully more fines will be given to others. Morgan Scamly, Leerink, and Goldman Sucks should be next.

User Image ILUVSPEWINGNONSENSE Posted - 1 day ago

$ARWR Criminal I tell ya... just criminal!

User Image LeftyT Posted - 1 day ago

@nycmax This is NOT fake news. It may be a blend of old $ALT news and new ALT news, but NONE of it is fake. The AE levels were lower than existing GLP products in the market today. The drop out rate was only 2.9% which was better than Viking trials, even though dose titration was not used. The liver fat reduction was best in class with only 12 weeks needed to bring most patients down under 5% "normal" levels. The Triglyceride reduction was the best I've seen for any drug tested to date (with the exception of $ARWR APOC3 which is in P3 right now) and that's just a side benefit for ALT The weight loss is comparable with all other drugs out there, and weight loss can be continued longer in future studies, especially since muscle loss factors are superior to EVERY drug in the weight loss sphere today. These are all FACTS and not fake news, so please just grow up and get some balance in your posts.

User Image skeezbag Posted - 1 day ago

$ARWR 1604 trader is now back showing proof of manis defense at the fake $29 target

User Image SBL71 Posted - 1 day ago

$ARWR Been pretty focused on my Viking position today...throw a little love here too...nice work .50 cent!! someday

User Image C_Bass Posted - 1 day ago

$ARWR boinggggg

User Image skeezbag Posted - 1 day ago

$ARWR everyone on this board should be filing an sec report against the Morgan, Leerink, Goldman trio after today.

User Image TheChosenWon Posted - 1 day ago

$ARWR every biotech I have on my ticker is positive except this one 🤣

User Image skeezbag Posted - 1 day ago

$ARWR lmmfao clown stock

User Image skeezbag Posted - 1 day ago

$ARWR over $29 Mani is fired and can go fuck himself or they self whatever it prefers

User Image C_Bass Posted - 2 days ago

$ARWR nice momentum in their chart for a change

User Image StreetwiseReports Posted - 2 days ago

Analyst Says CA Pharma Underappreciated by Investors: https://ow.ly/wEQR50SJybW Arrowhead Pharmaceuticals Inc. recently hosted a webinar going over its pulmonary programs. Read why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. #pharmastocks $ARWR

User Image skeezbag Posted - 2 days ago

$ARWR 100% on my $nvda puts right around the day @Rabinovich told us to buy $nvda

User Image Stock_Titan Posted - 2 days ago

$ARWR Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results https://www.stocktitan.net/news/ARWR/arrowhead-pharmaceuticals-to-webcast-fiscal-2024-third-quarter-hh3f2g7jz2f5.html

User Image Thestocktraderhubzee Posted - 2 days ago

WATCHLIST JUL 24 2024 $EXR Raymond James Maintains Outperform on Extra Space Storage, Raises Price Target to $175 $NXPI Needham Maintains Buy on NXP Semiconductors, Raises Price Target to $300 $NCNA Oppenheimer Reiterates Outperform on NuCana, Maintains $150 Price Target $ARWR HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target $YELP Morgan Stanley Maintains Underweight on Yelp, Raises Price Target to $34

User Image johnnygogogo Posted - 3 days ago

$ARWR my favorite threesome from left to right, Scamley, Mani, Goldfish representing the numbers 27, 29 and 31.

User Image smartkarma Posted - 3 days ago

$ARWR | Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas! "Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024." - Baptista Research (Baptista Research) Key Points: * Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024. * A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities. * In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders. Read more: https://www.smartkarma.com/insights/arrowhead-pharmaceuticals-expansion-of-trim-platform-and-entry-into-new-therapeutic-areas

User Image skeezbag Posted - 3 days ago

$ARWR Mani gets fired once over $29

User Image Article_AI Posted - 3 days ago

$ARWR Buy Rating Affirmed: Arrowhead Pharmaceuticals’ Advancements in RNAi Pulmonary Therapeutics Signal Market Growth Potential Arrowhead Pharmaceuticals (ARWR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Tr... https://www.stck.pro/news/ARWR/85912584/

User Image skeezbag Posted - 4 days ago

$ARWR 1604 trader slowly disappearing. 32.5 in play now on way to fake buyout valuation

User Image Mattie2 Posted - 4 days ago

$ARWR I should have bought DUK (Duke energy ). A dividend and pretty good stability. Hope SOMEONE buys this out …….and SOOOOON !

User Image C_Bass Posted - 1 week ago

$ARWR would be awesome to see a parabola here

User Image skeezbag Posted - 1 week ago

$ARWR keep pretending to make the chart look like shit for the buyout

User Image SBL71 Posted - 1 week ago

$ARWR

User Image johnnygogogo Posted - 1 week ago

$ARWR nobody liked my Arrowhead Schwarmaceuitcals joke, so how about a name change to 9DEMA Pharma or Gap Close Pharma? Speaking of gaps, I see 3 - one above from March 10/11, one below from July 10/11 and then there’s a bonus gap that only @skeezbag and I can see with our special goggle. Skeez, no telling, let’s make them look for it.

Analyst Ratings
HC Wainwright & Co. Buy Jul 23, 24
Chardan Capital Buy Jul 17, 24
HC Wainwright & Co. Buy Jul 5, 24
Chardan Capital Buy Jun 26, 24
Cantor Fitzgerald Overweight Jun 20, 24
HC Wainwright & Co. Buy Jun 11, 24
Goldman Sachs Neutral Jun 5, 24
HC Wainwright & Co. Buy Jun 3, 24
Chardan Capital Buy Jun 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 32.44 57,499 1,865,268 3,715,048 02/02/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Option 14.54 57,499 836,035 3,772,547 02/02/24
Hamilton James C Chief Discovery/Tran.. Chief Discovery/Trans Medicine Jan 12 Sell 36.92 7,940 293,145 210,851 01/17/24
GIVEN DOUGLAS B Director Director Jan 11 Sell 38.16 2,911 111,084 129,711 01/16/24
Waddill William D. Director Director Jan 11 Sell 38.2 3,934 150,279 47,870 01/16/24
Ferrari Mauro Director Director Jan 11 Sell 38.22 3,147 120,278 60,778 01/16/24
Vakiener Victoria Director Director Jan 11 Sell 38.36 4,720 181,059 32,001 01/16/24
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jan 04 Sell 33.89 74 2,508 136,501 01/08/24
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 04 Sell 34.89 16,104 561,869 440,600 01/08/24
San Martin Javier Chief Medical Office.. Chief Medical Officer Jan 04 Sell 34.93 8,303 290,024 198,497 01/08/24
Hamilton James C Other Other Jan 03 Sell 33.89 38,443 1,302,833 218,791 01/05/24
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 03 Sell 33.46 33,190 1,110,537 464,385 01/05/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 31 9,952 308,512 3,715,048 01/04/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 28.54 12,000 342,480 3,725,000 12/22/23
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 20 Sell 28.87 19,700 568,739 131,800 11/22/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 25 Sell 24.21 24,338 589,223 3,737,000 10/27/23
Vakiener Victoria Director Director Sep 28 Sell 26.33 1,550 40,812 21,734 10/02/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Sell 28.14 57,755 1,625,226 3,761,338 09/20/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Option 4.75 57,755 274,336 3,819,093 09/20/23
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 35.31 8,925 315,142 61,575 07/06/23
Hamilton James C Other Other Jun 30 Sell 35.53 3,000 106,590 188,484 07/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 36.20 15,000 543,000 381,704 06/29/23
GIVEN DOUGLAS B Director Director May 05 Sell 40.90 6,500 265,850 117,635 05/08/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Sell 39.38 104,928 4,132,065 3,761,338 05/05/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Option 2.01 104,928 210,905 3,811,338 05/05/23
OLUKOTUN ADEOYE Y Director Director Mar 03 Sell 32.65 11,350 370,578 7,867 03/06/23
GIVEN DOUGLAS B Director Director Feb 27 Sell 32.62 875 28,542 13,000 03/01/23
Waddill William D. Director Director Jan 09 Sell 30 3,200 96,000 28,950 01/11/23
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 05 Sell 37.39 15,000 560,850 413,375 01/06/23
Hamilton James C Other Other Jan 05 Sell 37.4 13,803 516,232 191,484 01/06/23
Hamilton James C Other Other Jan 03 Sell 39.05 10,338 403,699 145,287 01/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 40.00 30,625 1,225,000 336,704 12/30/22
O'Brien Patrick General Counsel General Counsel Dec 21 Option 6.15 32,000 196,800 380,875 12/22/22
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21